Company: INMB
Filing Date: 2025-12-10
Form Type: 8-K
Source: 0001213900-25-120067
Chunk: 0

Company: Inmune Bio, Inc.
Filing Date: 2025-12-10
Form: 8-K
Item: Item 1.02
Chunk 0
---
Item 1.02

Termination of a Material Definitive Agreement.

As previously disclosed, on August 9, 2024, INmune
Bio Inc. (the “ Company”) entered into an Amended and Restated At-The-Market Sales Agreement (the “ Sales Agreement”)
with RBC Capital Markets, LLC (“ RBC”) and BTIG, LLC (“ BTIG”), pursuant to which the Company could offer and sell
shares of its common stock, par value $0.001 per share (“ Common Stock”), having an aggregate offering price of up to $75,000,000,
from time to time through RBC and BTIG in “at-the-market offerings” as defined in Rule 415 of the Securities
Act of 1933, as amended.

On December 5, 2025 and December 9, 2025, pursuant
to and in accordance with Section 12(b) of the Sales Agreement, the Company notified RBC and BTIG, respectively, that the Company
is terminating the Sales Agreement, effective December 19, 2025. The Company is not subject to any termination penalties or other
expenses related to the termination of the Sales Agreement. Prior to termination, the Company issued and sold 1,353,469 shares of Common
Stock under the Sales Agreement, raising net proceeds of approximately $10.5 million.

The description of the Sales Agreement contained
in this Current Report on Form 8-K does not purport to be complete and is qualified in its entirety by reference to the copy of the Sales
Agreement filed as Exhibit 1.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on August 9, 2024.

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                               INMUNE BIO INC.                               
  Date: December 10, 2025      By:                  /s/ David Moss           
                                                    David Moss               
                                                    Chief Executive Officer